Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, 06112 Halle/ Saale, Germany.
Curr Cancer Drug Targets. 2019;19(3):210-221. doi: 10.2174/1568009618666180706165845.
The small leucine-rich proteoglycans (SLRPs) biglycan (BGN) and decorin (DCN) linked with sulfated glycosaminoglycan (GAG) chains exhibit oncogenic or tumor suppressive potentials depending on the cellular context and association with GAGs.
We hypothesized that structural alterations and expression levels of BGN, DCN and their associated chondroitin sulfate (CS) polymerizing enzymes, dermatan sulfate (DS) epimerases and various sulfatases might be correlated with the tumor (sub)type and patients' survival.
We acquired breast cancer (BC) and glioma patients' datasets from cBioPortal and R2 Genomics. Structural alterations and the expression pattern of CS polymerizing enzymes, DS epimerases and carbohydrate sulfotransferases (CHST) were compared to that of BGN and DCN and correlated to their clinical relevance.
In BC, no mutations, but amplifications (0.2 - 2.1 %) and deletions (0.05 - 0.4 %) were found in BGN, DCN and CS/DS enzymes. In contrast, missense and/or truncated mutations (0.1 - 0.5 %), but a reduced amplification rate (0 - 1.5 %) were found in glioma. When compared to BC, the structural abnormalities caused altered mRNA expression levels of BGN, DCN, GAG synthesizing enzymes and CHST. Mutations in SLPRs, CHSY1, CHST4 and CHSY3 were correlated with a poor prognosis in glioma, while lack of mutations and copy number variations in the SLRPs, CHSY3, CHST15 and DSE displayed an increased survival in BC.
A distinct association of BGN and DCN with CHST, CS polymerizing enzymes and DS epimerases was found in BC and glioma. Thus, a unique pattern of structural alterations and expression, which has clinical relevance, was found for PGs and GAG synthesizing enzymes and CHST in BC and glioma, which might help to identify high-risk patients and to develop personalized therapeutics.
富含亮氨酸的小蛋白聚糖 (SLRPs) 中的 biglycan (BGN) 和 decorin (DCN) 通过与硫酸化糖胺聚糖 (GAG) 链结合,具有致癌或肿瘤抑制潜力,具体取决于细胞环境以及与 GAG 的结合情况。
我们假设 BGN、DCN 及其相关的软骨素硫酸盐 (CS) 聚合酶、硫酸皮肤素 (DS) 差向异构酶和各种硫酸酯酶的结构改变和表达水平可能与肿瘤 (亚型) 和患者的生存有关。
我们从 cBioPortal 和 R2 Genomics 获得了乳腺癌 (BC) 和神经胶质瘤患者的数据集。比较了 CS 聚合酶、DS 差向异构酶和糖基转移酶 (CHST) 的结构改变和表达模式与 BGN 和 DCN 的表达模式,并与它们的临床相关性相关联。
在 BC 中,BGN、DCN 和 CS/DS 酶没有发现突变,但存在扩增 (0.2-2.1%)和缺失 (0.05-0.4%)。相比之下,在神经胶质瘤中发现了错义和/或截短突变 (0.1-0.5%),但扩增率降低 (0-1.5%)。与 BC 相比,SLPRs、CHSY1、CHST4 和 CHSY3 的结构异常导致 BGN、DCN、GAG 合成酶和 CHST 的 mRNA 表达水平发生改变。SLRPs、CHSY3、CHST15 和 DSE 中缺失突变和拷贝数变异与神经胶质瘤的不良预后相关,而在 BC 中 SLRPs、CHSY3、CHST15 和 DSE 中缺乏突变和拷贝数变异与生存增加相关。
在 BC 和神经胶质瘤中发现 BGN 和 DCN 与 CHST、CS 聚合酶和 DS 差向异构酶存在明显的关联。因此,在 BC 和神经胶质瘤中发现了 PGs 和 GAG 合成酶以及 CHST 的独特结构改变和表达模式,这与临床相关,这可能有助于识别高危患者并开发个性化治疗方法。